Amplix Expands Florida Presence with Acquisition of RAS3 Communications and Consulting
Founded in 2001 and headquartered in
"RAS3 has spent more than two decades earning the trust of its clients, and its relationship-driven culture makes it a strong fit for Amplix," said
"At RAS3, we have always started by understanding our clients' environments and advocating for their best interests," said
Following the acquisition, RAS3's leadership and team will join Amplix, with operations continuing under the Amplix brand.
About RAS3 Communications and Consulting
Founded in 2001 by
About Amplix
Amplix provides technology advisory services, including strategy, consulting, implementation, and managed services, to more than 3,500 clients nationwide, enabling data-driven technology decision-making and optimization. Amplix advisory services encompass strategy, consulting, implementation, and managed services in technology areas, including AI, cloud, infrastructure, security, unified communications, mobility, and business applications. Amplix is headquartered in
About Gemspring Capital
Gemspring Capital, a Westport, Connecticut-based private equity firm with $5.1 billion of capital under management, provides flexible capital solutions to middle market companies. Gemspring partners with talented management teams and takes a partnership approach to helping drive revenue growth, value creation and sustainable competitive advantages. Target companies have up to $2.0 billion in revenue and are in the business services, consumer services, financial and insurance services, healthcare, industrial, software, and tech-enabled services sectors. For more information, visit www.gemspring.com.
Contact: Zubin Malkani, [email protected]
View original content:https://www.prnewswire.com/news-releases/amplix-expands-florida-presence-with-acquisition-of-ras3-communications-and-consulting-302796551.html
SOURCE Gemspring Capital
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pixelgen Technologies Closes $15.5M Oversubscribed Series B to Accelerate Global Expansion
- Odysight.ai Inc. Announces Pricing of $11 million Public Offering of Common Stock
- Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Development of AKIR001 for the Treatment of Solid Tumors
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share